Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) improved invasive disease-free survival (IDFS) compared with trastuzumab emtansine (T-DM1; Kadcyla) as treatment for patients with HER2-positive early breast cancer with residual invasive disease in…
T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup
